Publicou 6 edições por ano
ISSN Imprimir: 1040-8401
ISSN On-line: 2162-6472
Indexed in
Immunological Effects of Thalidomide and Its Chemical and Functional Analogs
RESUMO
Thalidomide has recently shown considerable promise in the treatment of a number of conditions, such as leprosy and cancer. Its effectiveness in the clinic has been ascribed to wide-ranging properties, including anti-TNF-a, T-cell costimulatory and antiangiogenic activity. Novel compounds with improved immunomodulatory activity and side effect profiles are also being evaluated. These include selective cytokine inhibitory drugs (SelCIDsTM), with greatly improved TNF-a inhibitory activity, and immunomodulatory drugs (IMiDsTM) that are structural analogs of thalidomide, with improved properties. A third group recently identified within the SelCID group, with phosphodiesterase type 4–independent activity, is in the process of being characterized in laboratory studies. This review describes the emerging immunological properties of thalidomide, from a historical context to present-day clinical applications, most notably in multiple myeloma but also in other cancers, inflammatory disease, and HIV. We also describe the laboratory studies that have led to the characterization and development of SelCIDs and IMiDs into potentially clinically relevant drugs. Early trial data suggest that these novel immunomodulatory compounds may supercede thalidomide to become established therapies, particularly in certain cancers. Further evidence is required, however, to correlate the clinical efficacy of these compounds with their known immunomodulatory, antiangiogenic, and antitumor properties.
-
Lehman Thomas J.A., Schechter Sharon J., Sundel Robert P., Oliveira Sheila K., Huttenlocher Anna, Onel Karen B., Thalidomide for severe systemic onset juvenile rheumatoid arthritis: A multicenter study, The Journal of Pediatrics, 145, 6, 2004. Crossref
-
Briones Javier, Emerging therapies for B-cell non-Hodgkin lymphoma, Expert Review of Anticancer Therapy, 9, 9, 2009. Crossref
-
Amato Robert J., Sarao Harmeet, A Phase I Study of Paclitaxel/Doxorubicin/Thalidomide in Patients with Androgen-Independent Prostate Cancer, Clinical Genitourinary Cancer, 4, 4, 2006. Crossref
-
Adams Alexa, Lehman Thomas J.A, Update on the pathogenesis and treatment of systemic onset juvenile rheumatoid arthritis, Current Opinion in Rheumatology, 17, 5, 2005. Crossref
-
DePianta Robert, Douville Kenneth, Nickerson Beverly, Borjas Ricardo E., Chiral Screening Methods for Pharmaceutical Analysis and Purification in an Industrial Laboratory, in Chiral Separation Methods for Pharmaceutical and Biotechnological Products, 2010. Crossref
-
Yasui Kozo, Uchida Noriko, Akazawa Yohei, Nakamura Shinichi, Minami Isaki, Amano Yoshiro, Yamazaki Takashi, Thalidomide for treatment of intestinal involvement of juvenile-onset Behçet disease, Inflammatory Bowel Diseases, 14, 3, 2008. Crossref
-
Chanan-Khan Asher, Porter Carl W, Immunomodulating drugs for chronic lymphocytic leukaemia, The Lancet Oncology, 7, 6, 2006. Crossref
-
Kim Kyung-Jo, Update on the Treatment of Intestinal Behçet's Disease, Journal of Rheumatic Diseases, 21, 4, 2014. Crossref
-
Yasui Kozo, Yashiro Masato, Tsuge Mitsuru, Manki Akira, Takemoto Kei, Yamamoto Michiko, Morishima Tsuneo, Thalidomide dramatically improves the symptoms of early-onset Sarcoidosis/Blau syndrome: Its possible action and mechanism, Arthritis & Rheumatism, 62, 1, 2010. Crossref
-
Bruno Benedetto, Rotta Marcello, Giaccone Luisa, Massaia Massimo, Bertola Alessandra, Palumbo Antonio, Boccadoro Mario, New drugs for treatment of multiple myeloma, The Lancet Oncology, 5, 7, 2004. Crossref
-
Liu Yi, Li Hui, Matsui Osamu, The antiangiogenic effect of thalidomide on occult liver metastases: Anin vivostudy in mice, Journal of Gastroenterology and Hepatology, 24, 6, 2009. Crossref
-
García-Carrasco Mario, Fuentes-Alexandro Salvador, Escárcega Ricardo O., Rojas-Rodriguez Jorge, Escobar Luis E., Efficacité de la thalidomide dans les arthrites chroniques juvéniles à début systémique, Revue du Rhumatisme, 74, 9, 2007. Crossref
-
Diamanti Antonella, Capriati Teresa, Papadatou Bronislava, Knafelz Daniela, Bracci Fiammetta, Corsetti Tiziana, Elia Domenica, Torre Giuliano, The clinical implications of thalidomide in inflammatory bowel diseases, Expert Review of Clinical Immunology, 11, 6, 2015. Crossref
-
García-Carrasco Mario, Fuentes-Alexandro Salvador, Escárcega Ricardo O., Rojas-Rodriguez Jorge, Escobar Luis E., Efficacy of thalidomide in systemic onset juvenile rheumatoid arthritis, Joint Bone Spine, 74, 5, 2007. Crossref
-
Longo R., Cacciamani F., Naso G., Gasparini G., Pancreatic cancer: From molecular signature to target therapy, Critical Reviews in Oncology/Hematology, 68, 3, 2008. Crossref
-
Molica Stefano, Immunomodulatory drugs in chronic lymphocytic leukemia: A new treatment paradigm, Leukemia & Lymphoma, 48, 5, 2007. Crossref
-
Guirgis Adel A., Zahran Magdy A.H., Mohamed Amr S., Talaat Roba M., Abdou Bishoy Y., Agwa Hussein S., Effect of thalidomide dithiocarbamate analogs on the intercellular adhesion molecule-1 expression, International Immunopharmacology, 10, 7, 2010. Crossref
-
Chang Julie E., Kahl Brad S., Current Status of Targeted Therapies for Mantle Cell Lymphoma, Drugs, 71, 17, 2011. Crossref
-
Puzik Alexander, Thiel Annette, Faust Kirstin, Härtel Christoph, Thalidomide has anti-inflammatory properties in neonatal immune cells, Innate Immunity, 19, 1, 2013. Crossref
-
Maini R, Kv Patil, Mg Rainey, De Villiers F, Prj Ames, Fatal Cerebral Toxoplasmosis in a Heavily Immune Suppressed Patient with Waldentrom's Disease, Scottish Medical Journal, 53, 4, 2008. Crossref
-
Kuriakose Philip, Targeted Therapy for Hematologic Malignancies, Cancer Control, 12, 2, 2005. Crossref
-
Chng Wee Joo, Lau Lee Gong, Yusof Noorainun, Mow Benjamin M. F., Targeted Therapy in Multiple Myeloma, Cancer Control, 12, 2, 2005. Crossref
-
López-Relaño Juan, Martín-Adrados Beatriz, Real-Arévalo Irene, Lozano-Bartolomé Javier, Abós Beatriz, Sánchez-Ramón Silvia, Alonso Bárbara, Gómez del Moral Manuel, Martínez-Naves Eduardo, Monocyte-Derived Dendritic Cells Differentiated in the Presence of Lenalidomide Display a Semi-Mature Phenotype, Enhanced Phagocytic Capacity, and Th1 Polarization Capability, Frontiers in Immunology, 9, 2018. Crossref
-
Zhou Li, Verma Amit, Targeting Signal Transduction Pathways in Hematopoietic Disorders, in Molecular Basis of Hematopoiesis, 2009. Crossref
-
Palladino Michael A., Bahjat Frances Rena, Theodorakis Emmanuel A., Moldawer Lyle L., Anti-TNF-α therapies: the next generation, Nature Reviews Drug Discovery, 2, 9, 2003. Crossref
-
Riess Hanno, Antiangiogenic Strategies in Pancreatic Cancer, in Pancreatic Cancer, 177, 2008. Crossref
-
Badros Ashraf, Thalidomide in Patients with Relapsed Multiple Myeloma, in Myeloma Therapy, 2008. Crossref
-
de Fraia Pinto Livia, Compri Cecília Melleti, Fornari João Victor, Bartchewsky Waldemar, Cintra Dennys Eduardo, Trevisan Miriam, de Oliveira Carvalho Patrícia, Ribeiro Marcelo Lima, Velloso Licio A., Saad Mario J., Pedrazzoli José, Gambero Alessandra, The immunosuppressant drug, thalidomide, improves hepatic alterations induced by a high-fat diet in mice, Liver International, 30, 4, 2010. Crossref
-
Girolamo Francesco, Coppola Cristiana, Ribatti Domenico, Trojano Maria, Angiogenesis in multiple sclerosis and experimental autoimmune encephalomyelitis, Acta Neuropathologica Communications, 2, 1, 2014. Crossref
-
Hernandez-Ilizaliturri Francisco J., Reddy Nishitha, Holkova Beata, Ottman Edris, Czuczman Myron S., Immunomodulatory Drug CC-5013 or CC-4047 and Rituximab Enhance Antitumor Activity in a Severe Combined Immunodeficient Mouse Lymphoma Model, Clinical Cancer Research, 11, 16, 2005. Crossref
-
Hwang Sung Hee, Rait Antonina, Pirollo Kathleen F., Zhou Qi, Yenugonda Venkata Mahidhar, Chinigo Gary M., Brown Milton L., Chang Esther H., Tumor-targeting nanodelivery enhances the anticancer activity of a novel quinazolinone analogue, Molecular Cancer Therapeutics, 7, 3, 2008. Crossref